Key Points
- SVP Amy Beth Vanduyn sold 687 shares of Phreesia on Jan. 15 at an average price of $16.38 for about $11,253, reducing her position by 0.43% to 159,551 shares valued at roughly $2.61M.
- Several insiders (including the CFO and general counsel) executed coordinated sales on Jan. 15–16 totaling about 29,511 shares for roughly $483k, though each still retains a material stake in the company.
- Phreesia has a market cap of about $950M and recently beat quarterly EPS estimates ($0.10 vs. ($0.01)) with revenue up 12.7% year‑over‑year, but the company still shows negative net margin and ROE and carries a consensus "Moderate Buy" price target of $30.06.
Phreesia, Inc. (NYSE:PHR - Get Free Report) SVP Amy Beth Vanduyn sold 687 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $16.38, for a total value of $11,253.06. Following the completion of the transaction, the senior vice president directly owned 159,551 shares of the company's stock, valued at $2,613,445.38. This represents a 0.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Amy Beth Vanduyn also recently made the following trade(s):
- On Friday, January 16th, Amy Beth Vanduyn sold 2,202 shares of Phreesia stock. The shares were sold at an average price of $16.36, for a total value of $36,024.72.
- On Thursday, January 8th, Amy Beth Vanduyn sold 2,602 shares of Phreesia stock. The stock was sold at an average price of $17.01, for a total value of $44,260.02.
Phreesia Price Performance
PHR opened at $15.76 on Wednesday. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The company has a market cap of $950.23 million, a price-to-earnings ratio of -157.59 and a beta of 0.61. The stock has a fifty day simple moving average of $18.10 and a two-hundred day simple moving average of $23.09. Phreesia, Inc. has a 12-month low of $15.41 and a 12-month high of $32.76.
Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.11. The firm had revenue of $120.33 million for the quarter, compared to analysts' expectations of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The company's quarterly revenue was up 12.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.25) EPS. Research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Phreesia
Several institutional investors have recently modified their holdings of the business. Federated Hermes Inc. bought a new stake in Phreesia in the 3rd quarter worth about $32,000. Asset Management One Co. Ltd. purchased a new stake in shares of Phreesia during the 3rd quarter valued at about $45,000. State of Alaska Department of Revenue bought a new stake in shares of Phreesia in the third quarter worth approximately $83,000. Farther Finance Advisors LLC raised its holdings in shares of Phreesia by 9,375.0% during the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company's stock valued at $86,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Anchor Investment Management LLC bought a new position in Phreesia during the third quarter valued at approximately $118,000. 92.10% of the stock is owned by hedge funds and other institutional investors.
Key Stories Impacting Phreesia
Here are the key news stories impacting Phreesia this week:
- Neutral Sentiment: Although multiple executives sold shares, each still holds a material stake after the transactions (examples from filings: CFO Balaji Gandhi ~150,569 shares; General Counsel Allison Hoffman ~169,661; David Linetsky ~223,942; EVP Evan Roberts ~826,554; SVP Amy Beth Vanduyn ~157,349). These remaining holdings may reduce concerns that insiders have lost long‑term conviction.
- Negative Sentiment: Several insiders completed coordinated sales on Jan 15–16: CFO Balaji Gandhi, General Counsel Allison Hoffman, David Linetsky, Evan Roberts and SVP Amy Beth Vanduyn sold multiple blocks at roughly $16.36–$16.38. Combined, the filings show roughly 29,511 shares sold for about $483k — a visible amount given PHR’s recent price and elevated intraday volume. Links to the SEC Form 4 filings for each filer are below:
Read More.
Read More.
Read More.
Read More.
Read More.
Wall Street Analyst Weigh In
PHR has been the subject of a number of analyst reports. Canaccord Genuity Group decreased their target price on shares of Phreesia from $38.00 to $33.00 and set a "buy" rating for the company in a research note on Tuesday, December 9th. Weiss Ratings restated a "sell (e+)" rating on shares of Phreesia in a research note on Friday, October 31st. Needham & Company LLC reiterated a "buy" rating and set a $35.00 price objective on shares of Phreesia in a research note on Monday, December 8th. KeyCorp dropped their target price on Phreesia from $35.00 to $32.00 and set an "overweight" rating on the stock in a report on Wednesday, October 8th. Finally, DA Davidson raised their price target on Phreesia from $33.00 to $35.00 and gave the company a "buy" rating in a report on Tuesday, December 2nd. Seventeen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.06.
Get Our Latest Research Report on PHR
Phreesia Company Profile
(
Get Free Report)
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
